Vertex Pharmaceuticals (VRTX) Long-Term Debt Repayments (2011 - 2018)

Vertex Pharmaceuticals' Long-Term Debt Repayments history runs 8 years deep, the most recent figure standing at $8.1 million for Q4 2018.

• In Q4 2018, Long-Term Debt Repayments rose 76.56% year-over-year to $8.1 million; the TTM figure through Dec 2018 stood at $27.9 million (up 48.58% YoY), while the FY2018 annual figure was $27.9 million, up 48.58% from the prior year.
• Long-Term Debt Repayments was $8.1 million for Q4 2018 at Vertex Pharmaceuticals, up from $5.7 million in the prior quarter.
• In the past five years, Long-Term Debt Repayments ranged from a high of $264.1 million in Q3 2014 to a low of -$272.9 million in Q4 2014.
• Historically, Long-Term Debt Repayments has averaged $5.3 million across 5 years, with a median of $4.8 million in 2017.
• The sharpest annual moves came in 2014 and 2016: Long-Term Debt Repayments sank 1816.71% in 2014, then surged 13426.8% in 2016.
• A 5-year view of Long-Term Debt Repayments shows it stood at -$272.9 million in 2014, then soared by 107.21% to $19.7 million in 2015, then sank by 78.31% to $4.3 million in 2016, then rose by 7.97% to $4.6 million in 2017, then soared by 76.56% to $8.1 million in 2018.
• The last three Long-Term Debt Repayments figures came in at $8.1 million (Q4 2018), $5.7 million (Q3 2018), and $4.9 million (Q2 2018), per Business Quant data.